PARP inhibitor
Apr 27, 2017
Merck sells biosimilars; AbbVie’s PARP; Pharma heads; Biogen looks to M&A
Merck sells biosimilars business to Fresenius Merck has divested its biosimilars business to fellow German drug maker Fresenius in a deal potentially worth 670 million euros. The drug maker said the move is aligned with a strategy of focusing on innovative medicines while enabling it to exploit its biosimilars portf...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
